Clinical

Dataset Information

0

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (PARADIGM study)


ABSTRACT: Interventions: investigational material(s) Generic name etc : mFOLFOX6 + panitumumab INN of investigational material : Fluorouracil, calcium levofolinate, oxaliplatin, panitumumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Group P; OXA: 85 mg/m2/day 1, l-LV: 200 mg/m2/day 1, 5-FU iv: 400 mg/m2/day 1, 5-FU civ: 2400 mg/m2/day 1-3, panitumumab: 6 mg/kg; mFOLFOX6 + panitumumab combination therapy, once every two weeks control material(s) Generic name etc : mFOLFOX6 + bevacizumab INN of investigational material : Fluorouracil, calcium levofolinate, oxaliplatin, bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Group B; OXA: 85 mg/m2/day 1, l-LV: 200 mg/m2/day 1, 5-FU iv: 400 mg/m2/day 1, 5-FU civ: 2400 mg/m2/day 1-3, bevacizumab: 5 mg/kg; mFOLFOX6 + bevacizumab combination therapy, once every two weeks Primary outcome(s): 1.Overall survival (OS) for All Participants Timeframe: Up to approximately 60 months OS will be measured as the time from the date of randomization to the date of death due to any cause. 2.OS for Participants with Left-sided Tumors Timeframe: Up to approximately 60 months OS will be measured as the time from the date of randomization to the date of death due to any cause. The left-sided tumors are defined as primary tumors occupying a left-sided site include the descending colon, sigmoid colon, and rectum. Study Design: Randomized controlled trial, open, active control, parallel assignment

DISEASE(S): Colorectal Cancer

PROVIDER: 97964 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 97976 | ecrin-mdr-crc
| 2611228 | ecrin-mdr-crc
| 2658055 | ecrin-mdr-crc
| 97778 | ecrin-mdr-crc
| 100929 | ecrin-mdr-crc
| 2632097 | ecrin-mdr-crc
| 100336 | ecrin-mdr-crc
| 100333 | ecrin-mdr-crc
| 98099 | ecrin-mdr-crc
| 99902 | ecrin-mdr-crc